Trial Profile
An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms KIR
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 13 May 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 13 May 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.